Diagnostic Pathology: Open Access
Open Access

Abstract

Various diagnostic technologies have been used with relevance to genomics, lipidomics and proteomics to allow more sensitive interpretations with relevance to early cell dysfunction. The diagnostic technologies encompass the genome, transcriptome, proteome and metabolome (central dogma of biology) and determine the cell genome (nuclear receptors) and transcription factor alterations with relevance to concentrations of plasma lipids and proteins. The projected cost of plasma and cell biomarker analysis is expected to be approximately 52 billion dollars by the year 2020. Major efforts with biomarkers have been identified with plasma protein panels to assess progression and severity of diseases. In spite of laboratory medicine and various analyte measurements for chronic diseases early abnormal nuclear-mitochondria interactions have not been identified with toxic immune reactions involved in mitochondrial apoptosis and the induction of programmed cell death.

Biography

Dr. Ian Martins is a Reveiwer for international journals. Chief Editor for International Journal of Diabetes Research (2014-2017), Research and Reviews: Neuroscience (2016-2017), Journal of Diabetes and Clinical Studies. BIT Member (BIT Congress. Inc) with H-index of 43, (ResearchGate STATs (23), Mendeley STATS (20). Scientist for Science Advisory Board (USA)/Academic with Academia.edu. Citations > 3000. ResearchGate’s analysis available on google, Tweet, Facebook, Lindekin under Ian James Martins’ name > 96% of the international SCIENTISTS. Lifetime Membership by International Agency for Standards and Ratings as Fellow for Diabetes, Medical Science (Nutrition). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM.

E-mail: i.martins@ecu.edu.au